CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 89 enrolled
Drug / intervention
AZD7986, oral solution, 1 to 50 mg/mL +1 moredrug
Likely dose
AZD7986, oral solution, 1 to 50 mg/mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02303574
NCT02303574Phase 1Completed

A PHASE I, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND FOOD EFFECT OF SINGLE AND MULTIPLE ORAL DOSES OF AZD7986 IN HEALTHY VOLUNTEERS.

AstraZeneca·interventional·Posted Dec 1, 2014·Updated Dec 11, 2018

In Brief

A Phase 1 clinical trial evaluating AZD7986, oral solution, 1 to 50 mg/mL and Placebo, oral solution for Safety, Pharmacokinetics, Pharmacodynamics, Food Effect. Completed, enrolled 89 participants across 1 site.

Detailed Summary

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 1, 2014
Enrollment StartDec 3, 2014
Primary CompletionAug 3, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.6 years ago

Interventions

AZD7986, oral solution, 1 to 50 mg/mLdrug

Starting dose in single ascending dose part: 5 mg

Placebo, oral solutiondrug

Matching placebo